WO2007041432A3 - Cross-neutralization of hcv with recombinant proteins - Google Patents

Cross-neutralization of hcv with recombinant proteins Download PDF

Info

Publication number
WO2007041432A3
WO2007041432A3 PCT/US2006/038315 US2006038315W WO2007041432A3 WO 2007041432 A3 WO2007041432 A3 WO 2007041432A3 US 2006038315 W US2006038315 W US 2006038315W WO 2007041432 A3 WO2007041432 A3 WO 2007041432A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
cross
neutralization
recombinant proteins
neutralize
Prior art date
Application number
PCT/US2006/038315
Other languages
French (fr)
Other versions
WO2007041432A2 (en
Inventor
Michael Houghton
Original Assignee
Novartis Vaccines & Diagnostic
Michael Houghton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Michael Houghton filed Critical Novartis Vaccines & Diagnostic
Publication of WO2007041432A2 publication Critical patent/WO2007041432A2/en
Publication of WO2007041432A3 publication Critical patent/WO2007041432A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Immunogenic compositions comprising HCV immunogenic polypeptides that cross-neutralize multiple HCV genotypes, as well as methods of using the immunogenic polypeptides are described. In particular, the invention relates to compositions comprising HCV envelope polypeptides that cross-neutralize at least two HCV genotypes selected from HCV-1, HCV-2, HCV-3, HCV-4, HCV-5 and HCV-6. Preferably, the HCV envelope polypeptides cross-neutralize all six of these HCV genotypes.
PCT/US2006/038315 2005-09-30 2006-10-02 Cross-neutralization of hcv with recombinant proteins WO2007041432A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72263505P 2005-09-30 2005-09-30
US60/722,635 2005-09-30

Publications (2)

Publication Number Publication Date
WO2007041432A2 WO2007041432A2 (en) 2007-04-12
WO2007041432A3 true WO2007041432A3 (en) 2007-07-12

Family

ID=37847278

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/038315 WO2007041432A2 (en) 2005-09-30 2006-10-02 Cross-neutralization of hcv with recombinant proteins

Country Status (1)

Country Link
WO (1) WO2007041432A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105263517A (en) * 2013-05-15 2016-01-20 阿尔伯达大学董事会 E1e2 hcv vaccines and methods of use

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20090946A1 (en) 2009-05-28 2010-11-29 Novartis Ag EXPRESSION OF RECOMBINANT PROTEINS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026418A1 (en) * 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
WO2002045743A2 (en) * 2000-12-09 2002-06-13 Cambridge University Technical Services Limited Hcv vaccines
US6635257B1 (en) * 1998-06-24 2003-10-21 Innogentics N.V. Particles of HCV envelope proteins: use for vaccination
WO2004041853A2 (en) * 2002-11-08 2004-05-21 Innogenetics N.V. Hcv vaccine compositions comprising e1 and ns3 peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635257B1 (en) * 1998-06-24 2003-10-21 Innogentics N.V. Particles of HCV envelope proteins: use for vaccination
WO2000026418A1 (en) * 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
WO2002045743A2 (en) * 2000-12-09 2002-06-13 Cambridge University Technical Services Limited Hcv vaccines
WO2004041853A2 (en) * 2002-11-08 2004-05-21 Innogenetics N.V. Hcv vaccine compositions comprising e1 and ns3 peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEUNIER JEAN-CHRISTOPHE ET AL: "Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 12, March 2005 (2005-03-01), pages 4560 - 4565, XP002426143, ISSN: 0027-8424 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105263517A (en) * 2013-05-15 2016-01-20 阿尔伯达大学董事会 E1e2 hcv vaccines and methods of use
CN105263517B (en) * 2013-05-15 2021-03-26 阿尔伯达大学董事会 E1E2HCV vaccines and methods of use

Also Published As

Publication number Publication date
WO2007041432A2 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
WO2008121324A3 (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
GB0718984D0 (en) Structure of the hepatitis C virus NS5A protein
WO2007098267A3 (en) Pseudoinfectious flavivirus and uses thereof
WO2005056759A3 (en) Methods of generating variant proteins with increased host string content and compositions thereof
WO2007008657A3 (en) Hepatitis c virus inhibitors
WO2004075861A3 (en) Recombinant adeno-associated virus production
EP1768698A4 (en) Immunogenic compositions comprising hmgb1 polypeptides
ZA200703561B (en) Methods and compositions for improving recombinant protein production
WO2006017538A3 (en) Hk1-binding proteins
WO2004099231A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2007035716A3 (en) Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
WO2009022236A8 (en) Immunogen platform
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
WO2007049155A3 (en) Compositions comprising yersinia pestis antigens
EP1989316A4 (en) Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2005091856A8 (en) Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
WO2005118813A3 (en) Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
EP1765374A4 (en) Compositions, methods and uses for a novel family of peptides
WO2006060728A3 (en) Methods and compositions involving lcrv proteins
EP1858532A4 (en) Compositions and methods for less immunogenic protein formulations
IL186258A0 (en) Chimeric proteins, their preparation and pharmaceutical compositions containing them
WO2006047728A3 (en) Bmp gene and fusion protein
WO2008033556A3 (en) High pressure treatment of proteins for reduced immunogenicity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06815947

Country of ref document: EP

Kind code of ref document: A2